Biotech RadarJobs updated

COMPANY

CyanVac

cyanvacllc.com ↗

Clinical Phase 2

Keywords: vaccine infectious disease intranasal COVID-19 Mumps Covid19 CVXGA (CVXGA50) CVM150 CVM26

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

  1. Trial start 1: A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults source ↗
  2. Trial start 2: A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults source ↗
  3. Trial start 2: A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults source ↗
  4. Trial start 1: Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT05736835A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults2CompletedSep 21, 2023Dec 16, 2025 (actual)
NCT06742281A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults2CompletedDec 5, 2024Jun 15, 2026 (actual)
NCT06967181A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults1Active, not recruitingMay 14, 20252027-12 (estimated)
NCT04954287Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents1CompletedAug 6, 2021Jun 10, 2023 (actual)
Feedback